Effect of Long-Term Head and Neck Venous Outflow Obstruction on Cognitive Function: Evidence From Patients With Internal Jugular Vein Stenosis
Long-Term Head and Neck Venous Outflow Obstruction and Cognitive Function: Evidence From Patients With Internal Jugular Vein Stenosis-A Case-Control Study Combined With a Prospective Observational Cohort Study
This study aims to determine the effect of long-term head and neck venous outflow obstruction-specifically internal jugular vein stenosis (IJVS) caused by atlas transverse process compression with a stenosis rate ≥50%-on cognitive function, and to observe the cognitive outcomes of atlas transverse process resection combined with release and perfusion technique in routine clinical care. The study uses a case-control design to compare cognitive function between patients with IJVS and matched healthy controls, and a prospective cohort design to follow surgical and non-surgical cohorts for 6 months. The Montreal Cognitive Assessment (MoCA) total score is the primary cognitive measure. The target population per the protocol summary is image-confirmed IJVS due to atlas transverse process compression (stenosis ≥50%), with mild-to-moderate cognitive impairment (MoCA <26), aged 18-65 years.
研究概览
地位
详细说明
Internal jugular vein stenosis is an important cause of head and neck venous outflow obstruction, and extrinsic stenosis caused by bony compression of the atlas transverse process is common in clinical practice. Atlas transverse process decompression is currently used mainly to relieve somatic symptoms such as pulsatile tinnitus, headache, and dizziness; however, high-quality evidence on its systematic effect on cognitive function is lacking. This study is conducted within routine clinical care and does not add any additional invasive sampling or traumatic examinations. During standard management-surgical decompression or conservative treatment-cognitive function and imaging-based venous outflow indicators are observed longitudinally.
In the case-control component, patients with IJVS (disease duration ≥6 months) are matched 1:1 to healthy controls by age, sex, and years of education; MoCA total scores and cognitive subdomain scores are compared. In the cohort component, patients are assigned to a surgical cohort or a non-surgical cohort according to clinical indications and patient preference, without randomization or inducement. Follow-up is conducted at 1, 3, and 6 months after surgery or enrollment. The planned total cohort sample size is 72 participants (36 surgical and 36 non-surgical, allowing for a 10% dropout rate). Healthy controls for the case-control analysis are matched 1:1 and are not counted within the 72 cohort participants.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Zhiqiang Hu
- 电话号码:+8613144628367
- 邮箱:neuro7@163.com
研究联系人备份
- 姓名:Junpeng Xu
- 电话号码:+8613144628367
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Surgical cohort Procedure (routine clinical care, not a study intervention) Patients undergo atlas transverse process resection combined with release and perfusion technique according to clinical indications. The procedure aims to relieve bony compression of the internal jugular vein by the atlas transverse process. Postoperative follow-up is performed according to routine care. The study does not alter surgical indications or the operative procedure; it only observes changes in MoCA scores and imaging-based venous outflow indicators at 1, 3, and 6 months after surgery.
Healthy control group (case-control component) Observational comparator group Age-, sex-, and education-matched individuals without IJVS or head and neck venous outflow obstruction, matched 1:1 to the case group.
描述
Inclusion Criteria:
Cohort study (surgical cohort / non-surgical cohort):
Age 18-65 years, either sex. Confirmed by head and neck CT venography (CTV), MR venography (MRV), and jugular vein ultrasound as extrinsic IJVS caused by atlas transverse process compression, with a stenosis rate ≥50%.
Voluntary participation and signed written informed consent. Able to cooperate with MoCA cognitive assessment and related examinations at all scheduled time points.
No severe hepatic or renal insufficiency, coagulation disorders, or other severe underlying diseases.
Surgical cohort: no surgical contraindication and willingness to undergo atlas transverse process resection combined with release and perfusion technique. Non-surgical cohort: willingness to receive conservative treatment without surgery and no urgent surgical indication during follow-up.
Case-control study-case group:
Clinically confirmed IJVS with disease duration ≥6 months. CTV-confirmed IJVS caused by atlas transverse process compression. No history of previous cerebral infarction, intracranial hemorrhage, Alzheimer's disease, or other known causes of cognitive decline.
Complete baseline clinical and imaging data available.
Case-control study-healthy control group:
Age-, sex-, and education-matched individuals without IJVS, without head and neck venous outflow obstruction, and without severe organic disease or a history of cognitive impairment.
Exclusion Criteria
Cohort study:
Cognitive impairment caused by another definite etiology (e.g., Alzheimer's disease, cerebral infarction, cerebral hemorrhage, hypothyroidism).
Severe psychiatric disease preventing cooperation with cognitive assessment and study procedures.
Neck surgery, radiotherapy, or internal jugular vein intervention within the previous 3 months.
Pregnancy or breastfeeding. Malignant tumor, autoimmune disease, or other condition with an expected survival of less than 1 year.
Long-term use of sedative-hypnotics or cognitive-enhancing drugs that may affect MoCA assessment.
Refusal to participate in follow-up or inability to complete all scheduled assessments.
Case-control study:
Other imaging-detected venous abnormalities, such as venous sinus stenosis or jugular vein reflux, or the styloid process identified as the main compressive structure causing IJVS.
Severe heart failure or other major cardiac dysfunction. Severe hearing impairment or other conditions that may affect the validity or completion of cognitive assessment.
Intrathoracic or intracranial space-occupying lesions, cerebral vascular malformations, or other abnormalities on high-resolution chest CT, brain MRI, or CT that may constitute a major hemodynamic obstruction.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
IJVS
Internal Jugular Vein Stenosis |
|
HC
healthy controls |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in MoCA total score
大体时间:Baseline, 1 month, 3 months, and 6 months after surgery/follow-up
|
Change in the Montreal Cognitive Assessment total score from baseline to 6 months after surgery/follow-up. In the cohort component, between-group differences and repeated-measures trends are compared between the surgical and non-surgical cohorts. In the case-control component, baseline differences between cases and healthy controls are compared. |
Baseline, 1 month, 3 months, and 6 months after surgery/follow-up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
IJV stenosis improvement rate
大体时间:Baseline, 1, 3, and 6 months after surgery/follow-up
|
Imaging-based quantitative assessment of improvement in IJVS severity by CTV/ultrasound. |
Baseline, 1, 3, and 6 months after surgery/follow-up
|
|
Head and neck venous outflow patency
大体时间:Baseline, 1, 3, and 6 months
|
CTV/MRV assessment of venous sinus morphology, patency, and collateral circulation; ultrasound assessment of blood flow velocity and reflux. |
Baseline, 1, 3, and 6 months
|
|
Incidence of postoperative complications/adverse events
大体时间:Intraoperative period through 6-month follow-up
|
Bleeding, infection, hematoma, nerve stimulation, venous thrombosis, contrast agent reactions, etc. |
Intraoperative period through 6-month follow-up
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- BJSJTYY-IJVS-COG-2026
- IIT2026-063-001 (其他标识符:Ethics approval number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
We do not plan to share individual participant data (IPD). This is due to the strict requirements of the Personal Information Protection Law of the People's Republic of China and the local Ethics Committee regarding the protection of patient privacy and medical data, as the participants did not explicitly provide consent for public data sharing at the time of enrollment.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.